Charles River Gains 88.6% in a Year: What's Driving the Rally?

CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.

Zacks Investment Research • Aug 21, 2026

CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?

Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.

Zacks Investment Research • Aug 21, 2026

How an Insider CEO Is Taking a Fresh Look at Charles River

Even after 35 years and by her count 16 or 17 different jobs across every division at Charles River Laboratories, Birgit Girshick still made visiting the company's far-flung outposts one of her first priorities after taking over as CEO on May 5.

WSJ • Aug 20, 2026

Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC's next-generation multivalent.

Business Wire • Aug 20, 2026

International Markets and Charles River (CRL): A Deep Dive for Investors

Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Zacks Investment Research • Aug 10, 2026

Charles River Laboratories International Q2 Earnings Call Highlights

Charles River Laboratories International NYSE: CRL reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earnings and free-cash-flow guidance while maintaining a cautious view that the recovery in biopharmaceutical demand will progress gradually.

MarketBeat • Aug 6, 2026

This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga • Aug 6, 2026

Charles River lifts profit forecast on improving biotech demand

Contract drug developer Charles River Laboratories on Wednesday raised its annual profit forecast after quarterly results ​beat estimates, as it banked on stronger demand ‌for its drug discovery and development services from biotech clients.

Reuters • Aug 5, 2026

Charles River Blows Out Of A Buy Zone After One Metric Hits A Four-Year High

Shares of Charles River Laboratories blew out of a buy zone Wednesday after hitting its highest book-to-bill ratio in four years.

Investors Business Daily • Aug 5, 2026

Charles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcript

Charles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026